Business Wire

Boehringer Ingelheim and King’s College London Join Forces to Progress New Therapeutic Concepts in Major Depressive Disorder and Schizophrenia

Share

Boehringer Ingelheim and the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London today announced a new collaboration focused on understanding the malfunctions in brain circuits that drive impaired cognition in people with major depressive disorder (MDD) and schizophrenia (SZ). The study will aim to connect individual symptoms to specific brain-circuit dysfunctions, and will inform the development of novel therapies that target the underlying neurobiological processes of individual behavioral traits.

“We are delighted to collaborate with King’s IoPPN, a leading institute for research in psychiatry”, said Dr Vikas Mohan Sharma, Head of Medicine CNS, Retinopathies & Emerging Areas at Boehringer Ingelheim. “This collaboration will advance our understanding to better assess cognition and those biomarkers linked to cognitive deterioration in people with major depressive disorder and schizophrenia. We look forward to jointly creating opportunities to accelerate future clinical trials and the development of treatments for the many people impacted by psychiatric disorders.”

The partners plan to conduct four clinical studies to assess the behaviors of people with MDD and SZ in their home environments as well as during their study center visits where the activation of brain circuits triggered by cognitive tasks will be mapped. The unique study design includes, beyond standard clinical assessments, a battery of cognitive tasks, functional magnetic resonance imaging (fMRI), electroencephalography (EEG), polysomnography, patient functioning assessment through virtual reality tools and digital biomarkers to monitor speech and sleep habits.

“King’s College London has a long-standing focus on advancing the understanding of brain circuits responsible for cognition deficits in both psychiatric and neurological disorders,” said Professor Steven Williams, project lead and Head of Department of Neuroimaging at King’s IoPPN. “Working with Boehringer Ingelheim, a research-driven company with vast experience in central nervous system drug discovery and clinical development, will allow us to enlist their expertise in clinical study design, enable new therapeutic concepts and better clinical trials of individual patient populations.”

Neuropsychiatric disorders affect hundreds of millions of people worldwide and can impact people’s health and their ability to learn and work. Cognition is a fundamental aspect of everyday life, including problem-solving, memory and attention. When affected, people living with poor cognition can have a reduced mental ability to process information, remember straightforward things or perceive other people’s emotions and expressions. These malfunctions are common across many forms of mental disorders. Although antipsychotic medications have evolved in the 1990s since their introduction, treatment options have otherwise remained mostly unchanged. This is at least partly due to the lack of breakthrough therapies to treat severe mental health issues. Finding solutions for cognitive impairment is a key area of Boehringer Ingelheim’s innovative mental health research. The company has built a comprehensive development program in this area including two ongoing phase II trials and a recent first-of-its-kind phase III start for its novel glycine transporter-1 (GlyT1) inhibitor. The clinical study of GlyT1 is an example for the potential development of new therapeutic concepts based on better understanding of which brain circuits are relevant for cognitive impairment associated with schizophrenia.

Boehringer Ingelheim’s Intended Audiences Notice
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

Please click on the following link for ‘Notes to Editors’ and ‘References’:
http://www.boehringer-ingelheim.com/press-release/collaboration-kings-college-london

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contacts

Sarah Soetbeer
Boehringer Ingelheim Corporate Center GmbH
Communications + Public Affairs
P: +49 (6132) 77-183874
press@boehringer-ingelheim.com

Linda Ruckel
Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
P: +1 203-791-6672
press@boehringer-ingelheim.com

Patrick O’Brien
Senor Media Officer
Institute of Psychiatry, Psychology & Neuroscience, King’s College London
Media + PR
P: +44 (0)20-7848-5377
Patrick.1.obrien@kcl.ac.uk

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

H.I.G. Capital Announces the Sale of DGS S.p.A.11.6.2024 12:00:00 CEST | Press release

H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $62 billion of capital under management, is pleased to announce that an affiliate has signed a definitive agreement to sell its portfolio company, DGS S.p.A. (“DGS” or the “Group”), a leading firm in the Italian Information Technology market, to DGS Co-Founders and management team in partnership with ICG, a global alternative asset manager. Since its inception in 1997, DGShas supported blue-chip customers in the design, integration, and maintenance of complex IT systems, with a specialization in digital transformation and cybersecurity services. The Group currently has over 1,900 employees, revenues of approximately €300 million, and maintains a group of highly loyal clientele. During H.I.G.’s ownership, DGS has tripled in size and consolidated its position as a leading Italian firm in cybersecurity services and digital transformation. DGS offers its clients sophisticated and proprietary digital transformation

Evertas Names Nick Selby Head of European Underwriting11.6.2024 12:00:00 CEST | Press release

Evertas, the world’s first crypto insurance company, has named Nick Selby as its new Head of European Underwriting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611141887/en/ Nick Selby, Executive Vice President and Head of European Underwriting at Evertas (Photo: Business Wire) Selby, an accomplished information and physical security professional, brings two decades of expertise in public and private sector information security, physical security, and complex incident handling, as well as seven years of experience leading teams securing billions of dollars in cryptoassets. Previously, his roles included VP of the Software Assurance Practice at Trail of Bits, Chief Security Officer at Paxos Trust Company, and Director of Cyber Intelligence and Investigations at the NYPD Intelligence Bureau. “Nick is an extremely valuable addition to our European team,” said Evertas CEO and Co-Founder J. Gdanski. “His public and private

Owlet utvider globalt fotavtrykk med lanseringen av medisinsk-sertifisert Dream Sock™ i Storbritannia og over hele Europa11.6.2024 11:00:00 CEST | Pressemelding

Owlet, Inc. («Owlet» or the «Company») (NYSE:OWLT), pioneren innen smart spedbarnsovervåking, kunngjør i dag den britiske og europeiske lanseringen av Dream Sock. Dette er en smart babymonitor med levende helseavlesninger og varsler for friske spedbarn mellom 0-18 måneder og 2,5-13,6 kg. Dette innovative medisinske utstyret gir foreldre helse og viktig informasjon i sanntid, noe som gir uovertruffen trygghet. Denne pressemeldingen inneholder multimedia. Se hele pressemeldingen her: https://www.businesswire.com/news/home/20240611820341/no/ (Photo: Business Wire) «Vi er svært stolte over å lansere Dream Sock til omsorgspersoner over hele Storbritannia og Europa og gi millioner av foreldre mer trygghet mens babyen sover,» sa Kurt Workman, Owlets administrerende direktør og medgründer. «Dream Sock er nå et globalt produkt som er anerkjent som medisinsk nøyaktig og trygt, etter å ha gjennomgått regulatoriske autorisasjoner og sertifiseringer innenfor flere geografier. I dag er misjonen vår

V-Nova Surpasses 1000 Patent Milestone in Media Technology Innovation11.6.2024 10:00:00 CEST | Press release

V-Nova, a leading provider of data compression solutions, video compression technology, XR technology, AI acceleration and parallel processing for a multitude of industries including media and entertainment, today announced its milestone achievement of 1000 active technology patents. This accomplishment underscores V-Nova’s dedication to research and development and its commitment to protecting its intellectual property globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611724561/en/ V-Nova’s patent portfolio spans more than 50 different jurisdictions. Including over 400 patents in Europe, over 200 in the Americas, over 100 in the United States specifically, and over 200 in Asia. V-Nova forged new directions in data processing to enhance digital experiences, maximize efficiency, reduce costs, and increase sustainability. The company leads the way with key international data compression standards for the video indust

Alipay+ Reveals Top Scorer Trophy Design for UEFA EURO 2024™11.6.2024 09:24:00 CEST | Press release

Alipay+, a suite of cross-border mobile payment and digitalization technology solutions operated by Ant International and an Official Partner of UEFA EURO 2024™, today revealed the trophy that will be awarded to the most prolific marksman at the UEFA EURO 2024™ finale on July 14 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240610328619/en/ The UEFA Top Scorer Trophy presented by Alipay+ is unveiled for UEFA EURO 2024™ (Photo: Business Wire) Sculpted in the shape of the Chinese character “支” (pronounced zhi, and meaning payment as well as support), the trophy reflects Alipay+’s dedication to supporting consumers to enjoy seamless payment and a broad choice of deals using their preferred payment methods while traveling abroad. The character also resembles the fleeting moment of a barefooted striker poised to shoot, evoking the original beauty and power of football – a game that united people across the wo

World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye